Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Goldberg

Showing results (251-260 of 270) with videos related to

Pageof 27
Sort By:
Trials|June 18, 2015
AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trialMooketsi Molefi, Awilly A Chofle, Síle F Molloy, et al.
Nature Biotechnology|January 26, 2023
A universal deep-learning model for zinc finger design enables transcription factor reprogrammingDavid M Ichikawa, Osama Abdin, Nader Alerasool, et al.
The New England Journal of Medicine|March 23, 2013
A behavioral weight-loss intervention in persons with serious mental illnessGail L Daumit, Faith B Dickerson, Nae-Yuh Wang, et al.
BMC Psychiatry|December 15, 2010
Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trialSarah S Casagrande, Gerald J Jerome, Arlene T Dalcin, et al.
Journal for Immunotherapy of Cancer|April 7, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancerAlexey Revenko, Larissa S Carnevalli, Charles Sinclair, et al.
Schizophrenia Research|March 1, 2025
Building a two-state learning healthcare system for persons with first episode psychosisJill A Marsteller, Richard W Goldberg, Yasmine Boumaiz, et al.
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Journal of Dual Diagnosis|December 25, 2025
Talking About Cannabis: Perspectives of First Episode Psychosis Care Participants and ParentsAlicia Lucksted, Donna Bencivengo, Arunadevi Saravana, et al.
Molecular Cell|November 9, 2023
Manipulating the 3D organization of the largest synthetic yeast chromosomeWeimin Zhang, Luciana Lazar-Stefanita, Hitoyoshi Yamashita, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Pageof 27

Showing results (251-260 of 270) with videos related to

Sort By:
Pageof 27
Trials|June 18, 2015
AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trialMooketsi Molefi, Awilly A Chofle, Síle F Molloy, et al.
Nature Biotechnology|January 26, 2023
A universal deep-learning model for zinc finger design enables transcription factor reprogrammingDavid M Ichikawa, Osama Abdin, Nader Alerasool, et al.
The New England Journal of Medicine|March 23, 2013
A behavioral weight-loss intervention in persons with serious mental illnessGail L Daumit, Faith B Dickerson, Nae-Yuh Wang, et al.
BMC Psychiatry|December 15, 2010
Randomized trial of achieving healthy lifestyles in psychiatric rehabilitation: the ACHIEVE trialSarah S Casagrande, Gerald J Jerome, Arlene T Dalcin, et al.
Journal for Immunotherapy of Cancer|April 7, 2022
Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancerAlexey Revenko, Larissa S Carnevalli, Charles Sinclair, et al.
Schizophrenia Research|March 1, 2025
Building a two-state learning healthcare system for persons with first episode psychosisJill A Marsteller, Richard W Goldberg, Yasmine Boumaiz, et al.
Nature Communications|November 9, 2019
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activityJacqueline H L Fok, Antonio Ramos-Montoya, Mercedes Vazquez-Chantada, et al.
Journal of Dual Diagnosis|December 25, 2025
Talking About Cannabis: Perspectives of First Episode Psychosis Care Participants and ParentsAlicia Lucksted, Donna Bencivengo, Arunadevi Saravana, et al.
Molecular Cell|November 9, 2023
Manipulating the 3D organization of the largest synthetic yeast chromosomeWeimin Zhang, Luciana Lazar-Stefanita, Hitoyoshi Yamashita, et al.
Bioorganic & Medicinal Chemistry Letters|June 3, 2023
Optimization of a series of novel, potent and selective Macrocyclic SYK inhibitorsNeil P Grimster, Lakshmaiah Gingipalli, Amber Balazs, et al.
Pageof 27